Evidence map›Paper›PMID 34190602›Full record

ArticleMicrobiology spectrum2021

An Oral Fluorouracil Prodrug, Capecitabine, Mitigates a Gram-Positive Systemic Infection in Mice.

Jack R McLeod, Pamela A Harvey, Corrella S Detweiler

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Drug Repurposing: An Emerging Strategy inJournal of microbiology and biotechnology · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jack R McLeodDepartment of Molecular Cellular and Developmental Biology, University of Colorado, Boulder, Colorado, USA.
Pamela A Harvey *Department of Molecular Cellular and Developmental Biology, University of Colorado, Boulder, Colorado, USA.ORCID 0000-0001-9102-8823
Corrella S Detweiler *Department of Molecular Cellular and Developmental Biology, University of Colorado, Boulder, Colorado, USA.ORCID 0000-0002-7783-0876
University of Colorado Boulder · US

Funding

A Novel Screen for Antibacterials that Are Non-Toxic to MammalsR33AI121365 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S, WANG, XIANG · 2018 to 2020
$1.4M
A Novel Screen for Antibacterials that Are Non-Toxic to MammalsR21AI121365 · NIAID · UNIVERSITY OF COLORADO · PI DETWEILER, CORRELLA S, WANG, XIANG · 2016 to 2017
$412k
Howard Hughes Medical InstituteNIAID NIH HHS R21 AI121365NIAID NIH HHS R33 AI121365
6 · The paper itself

Abstract

New classes of antibiotics are needed to fight bacterial infections, and repurposing existing drugs as antibiotics may enable rapid deployment of new treatments. Screens for antibacterials have been traditionally performed in standard laboratory media, but bacterial pathogens experience very different environmental conditions during infection, including nutrient limitation. To introduce the next generation of researchers to modern drug discovery methods, we developed a course-based undergraduate research experience (CURE) in which undergraduate students screened a library of FDA-approved drugs for their ability, in a nutrient-poor medium, to prevent the growth of the human Gram-negative bacterial pathogen Salmonella enterica serovar Typhimurium. The nine drugs identified all disrupt DNA metabolism in bacteria and eukaryotes. One of the hit compounds, capecitabine, is a well-tolerated oncology drug that is administered orally, a preferred treatment route. We demonstrated that capecitabine is more effective at inhibiting

Indexed as

Administration, OralAnimalsAnti-Bacterial AgentsCapecitabineFemaleFluorouracilHumansMiceMice, Inbred BALB CProdrugsSalmonella typhimuriumStaphylococcal InfectionsAnti-Bacterial AgentsCapecitabineFluorouracilProdrugs5-fluorouracil (5-FU)antibioticscapecitabinecourse-based undergraduate research experience (CURE)nucleoside analogrepurposingSalmonella entericaStaphylococcus aureus

Identifiers

PMID34190602
PMCPMC8419118
OpenAlexW3174314478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.